N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.

N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.

Abnormalities in glycosphingolipid (GSL) biosynthesis have been implicated in the oncogenesis and malignancy of brain tumours. GSLs comprise the gangliosides and the neutral GSLs and are major components of the cell surface glycocalyx. N -butyldeoxynojirimycin (N B-DNJ) is an imino sugar that inhibi...

Full description

Bibliographic Details
Main Authors:	Ranes, M, El-Abbadi, M, Manfredi, MG, Mukherjee, P, Platt, F, Seyfried, T
Format:	Journal article
Language:	English
Published:	2001

Similar Items

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
by: Kasperzyk, J, et al.
Published: (2004)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
by: Baek, R, et al.
Published: (2004)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
by: Baek, R, et al.
Published: (2008)

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
by: Kasperzyk, J, et al.
Published: (2004)

Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
by: Kasperzyk, J, et al.
Published: (2002)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
by: Baek, R, et al.
Published: (2005)

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
by: Jeyakumar, M, et al.
Published: (2004)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
by: Denny, C, et al.
Published: (2010)

Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.
by: Heare, T, et al.
Published: (2007)

"Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice" (vol 46, pg 744, 2004)
by: Kasperzyk, J, et al.
Published: (2005)

Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin.
by: Walden, C, et al.
Published: (2006)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
by: Pelled, D, et al.
Published: (2003)

Altered expression of ganglioside metabolizing enzymes results in GM3 ganglioside accumulation in cerebellar cells of a mouse model of juvenile neuronal ceroid lipofuscinosis
by: Somogyi, A, et al.
Published: (2018)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
by: Andersson, U, et al.
Published: (2000)

Erratum: Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice (Journal of Lipid Research (April 2004) 46 (744-751))
by: Kasperzyk, J, et al.
Published: (2005)

N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice.
by: Priestman, D, et al.
Published: (2008)

Differential distribution of major brain gangliosides in the adult mouse central nervous system.
by: Katarina Vajn, et al.
Published: (2013-01-01)

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
by: Cox, T, et al.
Published: (2000)

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
by: Huebecker, M, et al.
Published: (2019)

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
by: Elstein, D, et al.
Published: (2004)

Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity
by: Yi-Chen Hsieh, et al.
Published: (2022-09-01)

The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.
by: Fischer, P, et al.
Published: (1995)

Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides
by: Pan, X, et al.
Published: (2017)

Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers
by: Maria Roxana Biricioiu, et al.
Published: (2024-01-01)

Gangliosides and Neuroblastomas
by: Cara-Lynne Schengrund
Published: (2020-07-01)

Ganglioside GM3 Synthase Deficiency in Mouse Models and Human Patients
by: Kei-ichiro Inamori, et al.
Published: (2022-05-01)

Ganglioside antibodies and neuropathies.
by: Rinaldi, S, et al.
Published: (2008)

The relationship between depletion of brain GM1 ganglioside and Parkinson's disease
by: Sandro Sonnino
Published: (2023-09-01)

GM1 ganglioside-independent intoxication by Cholera toxin
by: Cervin, J, et al.
Published: (2018)

N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery.
by: Pollock, S, et al.
Published: (2008)

N-butyldeoxynojirimycin (miglustat) ameliorates pulmonary fibrosis through inhibition of nuclear translocation of Smad2/3
by: Hiroyuki Nakamura, et al.
Published: (2023-04-01)

Gangliosides in Podocyte Biology and Disease
by: Berkan Savas, et al.
Published: (2020-12-01)

Gangliosides as Signaling Regulators in Cancer
by: Norihiko Sasaki, et al.
Published: (2021-05-01)

244 Targeting gangliosides in pediatric cancer
by: Min Huang, et al.
Published: (2023-11-01)

Mouse models of brain metastasis for unravelling tumour progression
by: Soto, MS, et al.
Published: (2016)

Gangliosides as Therapeutic Targets for Neurodegenerative Diseases
by: Orhan Kerim Inci, et al.
Published: (2024-01-01)

The Ying and Yang of Ganglioside Function in Cancer
by: Cara-Lynne Schengrund
Published: (2023-11-01)

Modulation of ROS production in human leukocytes by ganglioside micelles
by: M. Gavella, et al.
Published: (2010-10-01)

Gangliosides as Biomarkers of Human Brain Diseases: Trends in Discovery and Characterization by High-Performance Mass Spectrometry
by: Mirela Sarbu, et al.
Published: (2022-01-01)

Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation
by: Shani Blumenreich, et al.
Published: (2022-08-01)